Y-mAbs Partners with Nobelpharma for Japan Expansion
Company Announcements

Y-mAbs Partners with Nobelpharma for Japan Expansion

The latest update is out from Y-Mabs Therapeutics ( (YMAB) ).

Y-mAbs Therapeutics has signed an exclusive agreement with Nobelpharma to develop and commercialize DANYELZA in Japan for treating high-risk neuroblastoma, with potential expansion to relapsed osteosarcoma. Nobelpharma will manage regulatory submissions and marketing, while Y-mAbs will receive initial and milestone payments up to $31 million, plus royalties on future sales. This partnership marks a significant step in Y-mAbs’ global expansion efforts, aiming to improve treatment options for children battling advanced cancers.

Learn more about YMAB stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyY-mAbs, Nobelpharma announce exclusive license, distribution agreement
TheFlyY-mAbs Therapeutics announces new data on naxitamab, GD2-SADA
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App